Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Recent discoveries in stem cell transplant conditioning, mobilization, and expansion have ...
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Recent discoveries in stem cell transplant conditioning, mobilization, and expansion have the potential to improve the safety and efficacy of the procedure and allow more patients to obtain treatment. These scientific breakthroughs emerging from Harvard University and Children’s Hospital Boston have made it clear the field is ready for innovation. To translate these discoveries into therapeutics the leading life science venture capital firms, Third Rock Ventures and Atlas Venture have collaborated to create Magenta Therapeutics.
-
Number of Employees:
25-100
-
Annual Revenue:
$0-1 Million